AskGLP1 Turns Reddit Patient Stories Into a Knowledge Graph

2 Min Read

A new research paper posted on arXiv cs.AI introduces AskGLP1, an artificial intelligence system designed to process online discussions about GLP-1 weight management medications. The system scans millions of user posts on Reddit, filtering out relevant patient narratives and structuring them into a queryable knowledge graph. By utilizing large language models alongside the MedDRA medical terminology standard, AskGLP1 aims to connect informal patient accounts with formal pharmacovigilance data.

Mining Patient Narratives at Scale

As medications like semaglutide and related GLP-1 drugs gain widespread adoption for weight management, millions of users turn to online forums to document their journeys, side effects, and daily experiences. Traditionally, these vast repositories of real-world evidence remain unstructured, making it difficult for researchers and healthcare observers to aggregate insights efficiently. AskGLP1 attempts to bridge this gap by extracting specific medication experiences from a massive corpus of social media data, organizing thousands of individual testimonials into a structured framework that can answer targeted questions about patient outcomes.

Unresolved Questions and Future Monitoring

Despite the release of the technical details, the announcement did not specify the exact underlying large language models used within the pipeline, nor did it outline hardware requirements or computational costs for running the system. It remains unclear how the developers plan to address inherent biases in social media reporting, such as self-selection and unverified user claims. Observers will need to watch whether this knowledge graph approach is officially adopted by medical researchers or expanded to cover other therapeutic drug classes.

The project highlights a growing academic interest in applying natural language processing to social media data for health monitoring purposes.

Lead image: Bibek ghosh / Pexels

Share This Article